RU2017119065A3 - - Google Patents

Download PDF

Info

Publication number
RU2017119065A3
RU2017119065A3 RU2017119065A RU2017119065A RU2017119065A3 RU 2017119065 A3 RU2017119065 A3 RU 2017119065A3 RU 2017119065 A RU2017119065 A RU 2017119065A RU 2017119065 A RU2017119065 A RU 2017119065A RU 2017119065 A3 RU2017119065 A3 RU 2017119065A3
Authority
RU
Russia
Application number
RU2017119065A
Other languages
Russian (ru)
Other versions
RU2727802C2 (ru
RU2017119065A (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017119065A publication Critical patent/RU2017119065A/ru
Publication of RU2017119065A3 publication Critical patent/RU2017119065A3/ru
Application granted granted Critical
Publication of RU2727802C2 publication Critical patent/RU2727802C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
RU2017119065A 2014-11-07 2015-11-06 Апилимод для применения в лечении рака почек RU2727802C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462077127P 2014-11-07 2014-11-07
US62/077,127 2014-11-07
PCT/US2015/059512 WO2016073877A1 (en) 2014-11-07 2015-11-06 Apilimod for use in the treatment of renal cancer

Publications (3)

Publication Number Publication Date
RU2017119065A RU2017119065A (ru) 2018-12-07
RU2017119065A3 true RU2017119065A3 (OSRAM) 2019-06-05
RU2727802C2 RU2727802C2 (ru) 2020-07-24

Family

ID=54548302

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017119065A RU2727802C2 (ru) 2014-11-07 2015-11-06 Апилимод для применения в лечении рака почек

Country Status (16)

Country Link
US (3) US10206910B2 (OSRAM)
EP (2) EP3581184B1 (OSRAM)
JP (1) JP6705828B2 (OSRAM)
KR (1) KR20170098812A (OSRAM)
CN (1) CN107249638B (OSRAM)
AU (1) AU2015342869A1 (OSRAM)
BR (1) BR112017008799A2 (OSRAM)
CA (1) CA2966359A1 (OSRAM)
ES (1) ES2741399T3 (OSRAM)
HU (1) HUE044557T2 (OSRAM)
IL (1) IL251905B (OSRAM)
MX (1) MX377593B (OSRAM)
PL (1) PL3215158T3 (OSRAM)
PT (1) PT3215158T (OSRAM)
RU (1) RU2727802C2 (OSRAM)
WO (1) WO2016073877A1 (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112016017112A2 (pt) 2014-01-24 2017-08-08 Ai Therapeutics Inc Composições de apilimod e métodos de uso das mesmas
JP6705828B2 (ja) 2014-11-07 2020-06-03 エイアイ・セラピューティクス・インコーポレーテッド 腎癌の処置に使用するためのアピリモド
PT3215157T (pt) * 2014-11-07 2019-07-12 Ai Therapeutics Inc Apilimod para utilização no tratamento de melanoma
WO2017127661A1 (en) * 2016-01-21 2017-07-27 Lam Therapeutics, Inc. Biomarkers for treating cancer with apilimod
CA3034453A1 (en) * 2016-08-25 2018-03-01 AI Therapeutics, Inc. Compositions comprising pikfyve inhibitors and methods related to inhibition of rank signaling
CN110167559A (zh) * 2016-10-12 2019-08-23 人工智能治疗公司 阿匹莫德组合物和将其用于治疗阿尔茨海默病中的方法
WO2018175906A1 (en) 2017-03-24 2018-09-27 Nanosyn, Inc. Fused triazolo-pyrimidine compounds having useful pharmaceutical application
SG11202007130RA (en) 2018-01-26 2020-08-28 Univ California Methods and compositions for treatment of angiogenic disorders using anti-vegf agents
WO2019164861A1 (en) * 2018-02-21 2019-08-29 AI Therapeutics, Inc. Combination therapy with apilimod and glutamatergic agents
CA3168512A1 (en) 2019-11-25 2021-06-03 Napoleone Ferrara Long-acting vegf inhibitors for intraocular neovascularization
JP7744350B2 (ja) 2020-01-13 2025-09-25 バージ アナリティクス，インコーポレイテッド 置換ピラゾロ－ピリミジンおよびその使用
CN114306370A (zh) * 2021-12-31 2022-04-12 北京悦康科创医药科技股份有限公司 反义寡核苷酸在制备治疗肾癌药物中的应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
PT728218E (pt) 1993-11-12 2008-04-08 Phri Properties Inc Sondas de hibridação para detecção de ácidos nucleicos, troncos universais, métodos e estojos
US6693097B2 (en) 2001-11-30 2004-02-17 Synta Pharmaceuticals Corp. Pyrimidine compounds
AU2005213324B2 (en) 2004-02-06 2011-06-09 Biogen Idec Ma Inc. Methods and compositions for treating tumors and metastatic disease
WO2005112938A2 (en) 2004-04-13 2005-12-01 Synta Pharmaceuticals Corp. Disalt inhibitors of il-12 production
EP1791544A4 (en) 2004-09-08 2007-09-12 Chelsea Therapeutics Inc CHINAZOLINE DERIVATIVES AS METABOLIC INERT ANTIFOLATE
US7923557B2 (en) 2004-11-10 2011-04-12 Synta Pharmaceuticals Corporation Process for preparing trisubstituted pyrimidine compounds
US7863270B2 (en) 2005-05-13 2011-01-04 Synta Pharmaceuticals Corp. IL-12 modulatory compounds
WO2006128129A2 (en) * 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
KR20080078668A (ko) 2005-11-17 2008-08-27 오에스아이 파마슈티컬스, 인코포레이티드 융합된 바이사이클릭 ｍＴＯＲ 억제자
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
JP5156644B2 (ja) 2006-01-25 2013-03-06 オーエスアイ・フアーマシユーテイカルズ・エル・エル・シー 不飽和ｍＴＯＲ阻害剤
JP5215300B2 (ja) 2006-07-12 2013-06-19 ユニバーシティ オブ テネシー リサーチ ファウンデーション 置換アシルアニリドおよびそれらの使用方法
US8173647B2 (en) 2007-02-06 2012-05-08 Gordana Atallah PI 3-kinase inhibitors and methods of their use
RU2438664C2 (ru) 2007-05-15 2012-01-10 Пирамал Лайф Сайнсиз Лимитед Синергическая фармацевтическая комбинация для лечения рака
DE102007036076A1 (de) * 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5258331B2 (ja) 2008-03-03 2013-08-07 ロート製薬株式会社 光安定性が改善されたニューキノロン系抗菌剤含有医薬組成物
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
EP3023426A1 (en) 2008-07-17 2016-05-25 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
CN102844023B (zh) 2010-03-08 2016-01-20 索隆-基特林癌症研究协会 Cdc7激酶抑制剂以及其用途
CN106963741A (zh) * 2010-03-29 2017-07-21 Ea制药株式会社 含有苯基丙氨酸衍生物的医药制剂
US8402515B2 (en) 2010-05-06 2013-03-19 Jonathan Weizman Apparatus and method for establishing a peer-to-peer communication session with a client device
US20110287018A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of Treating Interstitial Cystitis
US8709419B2 (en) * 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
UA109557C2 (uk) 2010-11-19 2015-09-10 Похідні 2-піперазин-1-іл-4h-1,3-бензотіазин-4-ону та їх застосування для лікування інфекцій у ссавців
WO2013152342A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Anti-cancer mtor inhibitor and anti-androgen combination
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2013173223A1 (en) 2012-05-15 2013-11-21 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting pd-1/pd-l1 signaling
WO2014055913A1 (en) 2012-10-05 2014-04-10 Cerulean Pharma Inc. Treatment of cancer
US9295731B2 (en) 2013-04-01 2016-03-29 Mark Quang Nguyen Cleavable drug conjugates, compositions thereof and methods of use
BR112016017112A2 (pt) 2014-01-24 2017-08-08 Ai Therapeutics Inc Composições de apilimod e métodos de uso das mesmas
PT3215157T (pt) 2014-11-07 2019-07-12 Ai Therapeutics Inc Apilimod para utilização no tratamento de melanoma
JP6705828B2 (ja) 2014-11-07 2020-06-03 エイアイ・セラピューティクス・インコーポレーテッド 腎癌の処置に使用するためのアピリモド
KR101761573B1 (ko) 2014-12-29 2017-07-26 주식회사 인트론바이오테크놀로지 신규한 장출혈성 대장균 박테리오파지 Ｅｓｃ-ＣＨＰ-1 및 이의 장출혈성 대장균 증식 억제 용도
WO2016126707A1 (en) 2015-02-03 2016-08-11 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
WO2016160102A1 (en) 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
AU2019299234A1 (en) 2018-07-05 2021-01-14 Mayo Foundation For Medical Education And Research PIKfyve inhibitors
AR119934A1 (es) 2019-09-12 2022-01-19 Ai Therapeutics Inc Inhibidores de pikfyve para terapia contra el cáncer

Also Published As

Publication number Publication date
EP3581184B1 (en) 2021-02-24
JP6705828B2 (ja) 2020-06-03
IL251905A0 (en) 2017-06-29
EP3581184A1 (en) 2019-12-18
KR20170098812A (ko) 2017-08-30
CN107249638A (zh) 2017-10-13
WO2016073877A1 (en) 2016-05-12
US20190201385A1 (en) 2019-07-04
US10206910B2 (en) 2019-02-19
PT3215158T (pt) 2019-08-23
CA2966359A1 (en) 2016-05-12
MX2017006015A (es) 2017-11-17
EP3215158A1 (en) 2017-09-13
US20200297706A1 (en) 2020-09-24
BR112017008799A2 (pt) 2017-12-19
US11166944B2 (en) 2021-11-09
ES2741399T3 (es) 2020-02-10
US20170333408A1 (en) 2017-11-23
AU2015342869A1 (en) 2017-06-15
JP2017535601A (ja) 2017-11-30
RU2727802C2 (ru) 2020-07-24
HUE044557T2 (hu) 2019-11-28
IL251905B (en) 2021-03-25
CN107249638B (zh) 2021-05-14
EP3215158B1 (en) 2019-05-08
MX377593B (es) 2025-03-10
RU2017119065A (ru) 2018-12-07
PL3215158T3 (pl) 2019-11-29

Similar Documents

Publication Publication Date Title
BR112016016552A2 (OSRAM)
BR112016017979A2 (OSRAM)
BR112016017278A2 (OSRAM)
BR112016016225A2 (OSRAM)
BR112016016602A2 (OSRAM)
BR112016016245A2 (OSRAM)
BR112016018948A2 (OSRAM)
BR112016016708A2 (OSRAM)
BR112016017337A2 (OSRAM)
BR112016013761A2 (OSRAM)
BR112016016612A2 (OSRAM)
BR112016018580A2 (OSRAM)
BR112016016689A2 (OSRAM)
BR112016018369A2 (OSRAM)
BR112016017083A2 (OSRAM)
BR112016018468A2 (OSRAM)
BR112016016451A2 (OSRAM)
BR112016011585A2 (OSRAM)
BR112016019248A2 (OSRAM)
BR112016016823A2 (OSRAM)
BR112016018564A2 (OSRAM)
BR112016015666A2 (OSRAM)
BR112016017660A2 (OSRAM)
BR112016015243A2 (OSRAM)
BR112016016992A2 (OSRAM)

Legal Events

Date Code Title Description
HZ9A Changing address for correspondence with an applicant